从个股表现来看，今天上涨个股超4100家，下跌个股1000余家，涨停个股87家，跌停个股3家，可以看出今天算是一个普涨行情。从连板情绪来看， 上周五2连板及以上个股12家，今天真正晋级的只有4家，还有一家菲林格尔收盘竞价达到涨停价，但是没有封死，晋级率比较差，且2连板5家没有1 家晋级3连板，这在今天普涨的行情中也是非常少见的，算的上是一个罕见奇观了。不过目前市场有一个好的情况是：如联化科技、均瑶健康、菲林 格尔等这些周末都是被监控或是有利空的个股，今天还能涨停，说明短线情绪开始起来了。 盘面上来看，我在昨天的文章中提到的要关注"可控核聚变的反弹修复、足球概念、以及创新药、稳定币的资金回流修复等"。那么反观今天的市场表 现，可以说最强的就是创新药板块，创新药概念再度爆发，舒泰神、常山药业、海辰药业、睿智医药、联化科技、众生药业等多股涨停。消息面上， 国家药监局批准11款全新创新药的上市申请，另外还有2款创新药拟纳入优先审评，新品种密集获批有望赶上今年医保谈判放量，为相关企业业绩增 长提供助力。 另外，足球概念持续活跃，康力源20cm涨停、粤传媒涨停、共创草坪6连板，金陵体育涨超15%。可控核聚变午后活跃，百利 ...

Group 1 - The A-share controllable nuclear fusion sector experienced a short-term surge, with significant gains in related stocks [1] - Silver and non-ferrous metals stocks, including Baili Electric, hit the daily limit up, indicating strong market interest [1] - Other companies such as Zhongzhou Special Materials, Xue Ren Co., Changfu Co., Wangzi New Materials, and Shun Na Co. also saw increases in their stock prices, reflecting a broader trend in the sector [1]

Investment Rating - The report maintains a positive outlook on the controllable nuclear fusion industry, indicating a strong belief in the investment opportunities across the entire industry chain [3][4]. Core Insights - The controllable nuclear fusion technology is transitioning from laboratory research to engineering verification, with significant advancements in China and international collaboration through the ITER project [3][5]. - The global controllable nuclear fusion market is projected to grow from $331.49 billion in 2024 to $479.5 billion by 2029, with a substantial construction phase expected between 2025 and 2035 [3][4]. - The report emphasizes the importance of high-barrier and high-value segments within the industry chain, recommending specific companies for investment [4][5]. Summary by Sections 1. Controllable Nuclear Fusion: Progress Towards the "Eternal" 50 Years - The D-T reaction is identified as the mainstream approach for nuclear fusion, offering high energy density and sustainability compared to traditional nuclear fission [14][21]. - The magnetic confinement route is confirmed as the dominant technical pathway, with significant research and development efforts in China [26][27]. 2. Global Fusion Landscape: ITER and International Cooperation - The ITER project is highlighted as the largest international scientific collaboration aimed at developing a self-sustaining nuclear fusion reactor, with China playing a crucial role [48][51]. - Various countries are increasing their investments in fusion energy, with significant funding allocated to projects like ITER and national initiatives [61][63]. 3. China's Rise in Fusion Technology - China is advancing rapidly in nuclear fusion technology, with multiple research institutions and private companies contributing to the development of various fusion routes [3][5]. - The BEST project in China has commenced ahead of schedule, indicating a robust pace in fusion technology development [3][5]. 4. Market Potential and Investment Opportunities - The report forecasts a market space of approximately $203.5 billion for controllable nuclear fusion from 2025 to 2035, with a focus on high-value segments such as superconducting materials and core components [3][4]. - Recommended companies for investment include Lianchuang Optoelectronics, Guoguang Electric, and others involved in the high-barrier segments of the industry [4][5].

Investment Rating - Industry rating is maintained at "Outperform" [1] Core Insights - The report highlights significant breakthroughs in China's controllable nuclear fusion technology, with the "Chinese Circulation No. 3" achieving a plasma current of one million amperes and ion temperature reaching 100 million degrees, marking a new high in fusion parameters [3][6] - The advancements in nuclear fusion technology position China as a leader in the field, paving the way for future commercialization and potential growth opportunities for related upstream and downstream enterprises [3] Summary by Sections Industry Overview - The report discusses the continuous progress in controllable nuclear fusion technology in China, with key projects like the "Xuanlong-50U" achieving critical engineering breakthroughs [3][4] - The comprehensive parameters of fusion triple product have reached the order of 10^20, indicating significant advancements in the field [3] Key Companies to Watch - Recommended companies include: - Lianchuang Optoelectronics, a leading supplier of high-temperature superconducting magnets, which are crucial for compact tokamak devices [4] - Yongding Co., a major supplier of high-temperature superconducting strips [4] - Guoguang Electric, which provides various components for controllable nuclear fusion devices [4]

Core Viewpoint - The article highlights the performance of the top-performing stocks in May, emphasizing the significant gains in various sectors, particularly in logistics, innovative pharmaceuticals, and controlled nuclear fusion concepts [3][4]. Group 1: Stock Performance - As of May 30, the Shanghai Composite Index increased by 2.09%, the Shenzhen Component Index rose by 1.42%, and the ChiNext Index gained 2.32% during the month [3]. - Among the top ten stocks, 中邮科技 (China Post Technology) had the highest increase of 157.28%, followed by 舒泰神 (Shutai Shen) with 145.37%, and 王子新材 (Wangzi New Materials) with 108.37% [4][5][6]. Group 2: Company Highlights - 中邮科技 (China Post Technology) focuses on smart logistics systems, with a market capitalization of 9.1 billion yuan as of May 30. The stock price surged from 26 yuan to 67 yuan during May [5]. - 舒泰神 (Shutai Shen) specializes in innovative biopharmaceuticals, with core products including the national class I new drug "苏肽生" and a constipation treatment "舒泰清" [7]. - 王子新材 (Wangzi New Materials) is involved in controlled nuclear fusion, with its stock experiencing significant volatility. The company clarified that its involvement in fusion projects is limited and does not significantly impact its revenue [8]. - 合锻智能 (HeDuan Intelligent) also operates in the controlled nuclear fusion sector, reporting over 200 million yuan in orders for core components of Tokamak devices [9]. - 路桥信息 (LuQiao Information) focuses on traffic information solutions and saw a stock increase of 102.64% during May [10]. - 成飞集成 (Chengfei Integration) reported a 99.52% increase in stock price, with its main business in automotive parts and tools [11]. - 三生国健 (SanSheng GuoJian) announced a collaboration with Pfizer for a dual-specific antibody, with a record upfront payment of 1.25 billion USD for the licensing agreement [12][13]. - *ST亚振 (ST Yazhen) experienced a 93.14% increase, attributed to a change in controlling shareholder, which is expected to enhance the company's operational support [14]. - 中洲特材 (Zhongzhou Special Materials) is involved in high-temperature corrosion-resistant alloys but clarified that its products are not yet applied in controlled nuclear fusion [15]. - 七丰精工 (Qifeng Precision) aims for a 10.02% revenue growth in 2024, focusing on aerospace and rail transportation sectors [16].

Market Performance - As of May 30, the Shanghai Composite Index increased by 2.09% in May, the Shenzhen Component Index rose by 1.42%, and the ChiNext Index gained 2.32% [1] Top Performing Stocks - The top-performing stock in May was Zhongyou Technology, with a cumulative increase of 157.28%, driven by the dual forces of cost reduction and intelligent upgrades in the logistics industry [3][6] - Shutaishen ranked second with a cumulative increase of 145.37%, attributed to its innovative drug projects [3][7] - Wangzi New Materials achieved a 108.37% increase, with significant media attention on its involvement in controlled nuclear fusion [3][8] - Hezhuan Intelligent also saw a 108.16% increase, supported by its core component manufacturing capabilities for Tokamak devices in nuclear fusion applications [3][10] - Luqiao Information, a company listed on the Beijing Stock Exchange, experienced a 102.64% increase, focusing on information technology solutions in the transportation sector [3][11] - Chengfei Integration recorded a 99.52% increase, with its main business in automotive parts and tools [3][12] - San Sheng Guojian had a 99.45% increase, following a significant licensing agreement with Pfizer for its innovative drug [3][13] - ST Yazhen saw a 93.14% increase, linked to a change in its controlling shareholder [3][14] - Zhongzhou Special Materials, another controlled nuclear fusion concept stock, increased by 92.87%, although its products are not yet applied in that field [3][15] - Qifeng Precision Engineering, a military stock, increased by 90.58%, with a focus on aerospace and rail transportation markets [3][17]

可控核聚变行业由于较高的技术门槛，较少的企业参与其中，且当前仍处于技术攻关阶段，商业化不 足，科研主体为中国科学院合肥物质研究院等离子体物理研究所和核工业西南物理研究院(隶属于中国 核工业集团有限公司)等研究机构，项目建设中向相关企业采购相关材料设备。中国核建承担ITER核心 安装工程，掌握全超导托卡马克装置建造技术;中国核电牵头组建可控核聚变创新联合体，并于2025年2 月斥资10亿元入股中国聚变能源公司，这两家是国内可控核聚变产业的龙头企业。此外，西部超导、永 鼎股份、联创光电、上海电气等企业也参与了可控核聚变装置中关键器件的布局，能量奇点、瀚海聚 能、星环聚能等民营企业也参与可控核聚变中部分关键设计和技术研发工作。 行业主要上市公司：安泰科技(000969.SZ)，中国广核(003816.SZ)，永鼎股份(600105.SH)，西部超导 (688122.SH)，上海电气(601727.SH)等 中国可控核聚变行业整体竞争格局 中国可控核聚变行业市场区域竞争格局 通过企查猫，通过检索"可控核聚变"、登记状态为"存续/在业"的机构，截至2025年3月25日，中国相关 企业及研究院所共计170家，从我国可控核 ...

| 全A | 涨 1116 | 平 134 | 跌 4158 A股成 | | --- | --- | --- | --- | | 序号 代码 | 名称 | 现价 | 涨跌 涨跌幅 | | 1 | 000001 上证指数 | 3347.49 c | -15.96 -0.47% | | 2 | 399001 深证成指 | 10040.63c | -86.58 -0.85% | | 3 | 899050 北证50 | 1408.69 c | -7.16 -0.51% | | 4 | 881001 万得全A | 5074.29 c | -42.21 -0.83% | | 5 | 000688 889000 | 977.03 c | -9.28 -0.94% | | 6 | 399006 创业板指 | 1993.19c | -19.36 -0.96% | | 1 | 000300 沪深300 | 3840.23 c | -18.47 -0.48% | 沪深两市全天成交额1.14万亿，个股跌多涨少，全市场超4100只个股下跌。 盘面上看，猪肉股全天强势，创新药、银行等板块涨幅居前；可控核聚变、机器人、无人驾驶等板块跌幅 ...

5月30日，截至收盘，沪指跌0.47%，深成指跌0.85%，创业板指跌0.96%。 | 全A | 涨 1116 | 平 134 | 跌 4158 A股成 | | --- | --- | --- | --- | | 序号 代码 | 名称 | 现价 | 涨跌 涨跌幅 | | 1 | 000001 上证指数 | 3347.49 c | -15.96 -0.47% | | 2 | 399001 深证成指 | 10040.63c | -86.58 -0.85% | | 3 | 899050 北证50 | 1408.69 c | -7.16 -0.51% | | 4 | 881001 万得全A | 5074.29 c | -42.21 -0.83% | | 5 | 000688 889000 | 977.03 c | -9.28 -0.94% | | 6 | 399006 创业板指 | 1993.19 c | -19.36 -0.96% | | 7 | 000300 沪深300 | 3840.23 c | -18.47 -0.48% | 沪深两市全天成交额1.14万亿，个股跌多涨少，全市场超4100只个股下跌。 盘面上看 ...

Core Viewpoint - The concept of controllable nuclear fusion is gaining significant attention in the market, with Bai Li Electric (600468) experiencing a strong surge, hitting the daily limit and driving the entire sector upward [1] Industry Overview - The surge in controllable nuclear fusion stocks has led to a noticeable increase in related sectors, with multiple stocks in the sector rising, including Ha Han Hua Tong with a 20% increase and Rong Fa Nuclear Power also hitting the limit [1] - The upstream materials sector is poised for opportunities, particularly in superconducting materials, as the era of large-scale application of high-temperature superconducting tape materials like REBCO begins, which can provide stronger magnetic fields for nuclear fusion reactions [1] - Tungsten and tungsten-based alloys are identified as ideal first-wall materials due to their high melting points and thermal conductivity, with China holding the world's largest tungsten resource reserves, potentially leading to growth in this industry [1] Midstream Equipment Manufacturing - The midstream equipment manufacturing sector is a direct beneficiary, with superconducting magnets being core components of the devices, where high-temperature superconducting magnets can significantly enhance magnetic field strength, accounting for 40%-50% of total investment costs [1] - The first wall, located at the innermost part of the fusion device, plays a crucial role in protecting device components, indicating potential growth for related manufacturing sectors [1] - The偏滤器, typically located at the top and bottom of the vacuum chamber, controls the interaction between plasma and the chamber walls, reducing thermal load and particle bombardment, benefiting related manufacturing enterprises as the industry develops [1] Downstream Applications - The power generation sector is expected to be the first to benefit, as nuclear fusion's thermal energy can be converted into electricity through nuclear power plants, providing a large amount of clean and sustainable energy [1] - The medical field may also see growth through the use of isotopes produced by nuclear fusion for diagnostic and therapeutic purposes, contingent on technological maturity [1] Market Outlook - The construction of the "Kua Fu" project, the world's first domestically designed and built key system for fusion reactor mainframe, is entering a critical phase, alongside the early launch of domestic compact fusion energy experimental device engineering, indicating a faster transition from laboratory to engineering [1] - With dual support from policy and technology, the market prospects for this field are broad, likely attracting more capital into the related industry chain, and the activity of related concept stocks is expected to continue to rise [1]